Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6911461 | UCB INC | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
Feb, 2026
(3 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10729653 | UCB INC | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives |
Apr, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Aug 27, 2024 |
Drugs and Companies using BRIVARACETAM ingredient
Market Authorisation Date: 12 May, 2016
Treatment: Treatment of partial-onset seizures as adjunctive therapy in patients with epilepsy aged 16 years and older with epilepsy; Treatment of partial onset seizures in patients with epilepsy aged 16 years and older with epilepsy
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8802142 | UCB INC | Pharmaceutical compositions comprising levetiracetam and process for their preparation |
Jun, 2031
(8 years from now) | |
US8802142
(Pediatric) | UCB INC | Pharmaceutical compositions comprising levetiracetam and process for their preparation |
Dec, 2031
(8 years from now) |
Drugs and Companies using LEVETIRACETAM ingredient
Market Authorisation Date: 30 November, 1999
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7858122 | UCB INC | Extended release formulation of levetiracetam |
Sep, 2028
(5 years from now) |
Drugs and Companies using LEVETIRACETAM ingredient
Market Authorisation Date: 12 September, 2008
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9687495 | UCB INC | Methods and systems for the delivery of a therapeutic agent |
Jan, 2028
(4 years from now) | |
US9289432 | UCB INC | Methods and compositions for the delivery of a therapeutic agent |
Jan, 2028
(4 years from now) | |
US8217033 | UCB INC | Methods and compositions for the delivery of a therapeutic agent |
Jan, 2028
(4 years from now) | |
US8809322 | UCB INC | Methods and compositions for the delivery of a therapeutic agent |
Jan, 2028
(4 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | May 21, 2022 |
Orphan Drug Exclusivity (ODE) | May 17, 2026 |
Drugs and Companies using MIDAZOLAM ingredient
Market Authorisation Date: 17 May, 2019
Treatment: Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older
Dosage: SPRAY;NASAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8617591 | UCB INC | Transdermal delivery system for the administration of rotigotine |
Jul, 2023
(5 months from now) | |
US8246980 | UCB INC | Transdermal delivery system |
Nov, 2025
(2 years from now) | |
US8246979 | UCB INC | Transdermal delivery system for the administration of rotigotine |
Sep, 2027
(4 years from now) | |
US10130589 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Dec, 2030
(7 years from now) | |
US10350174 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Dec, 2030
(7 years from now) | |
US9925150 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Mar, 2032
(9 years from now) |
Drugs and Companies using ROTIGOTINE ingredient
Market Authorisation Date: 09 May, 2007
Treatment: A method for the treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the claimed transdermal delivery system (tds) to the skin of the patient; Treatment of signs and symptoms of parkinson's disease by application of claimed transdermal system; Treatment of restless legs syndrome by application of claimed transdermal delivery system
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
USRE38551 | UCB INC | Anticonvulsant enantiomeric amino acid derivatives |
Mar, 2022
(10 months ago) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Nov 16, 2023 |
New Patient Population (NPP) | Oct 14, 2024 |
Drugs and Companies using LACOSAMIDE ingredient
Market Authorisation Date: 28 October, 2008
Treatment: Method of treating partial onset seizures in patients 4 years of age and older; Method of treating, as initial loading dose for monotherapy or adjunctive therapy, partial onset-seizures in a patient with epilepsy aged 17 years or older; Method of use of treating, as an initial loading dose for monotherapy or adjunctive therapy in partial onset seizure patients with epilepsy aged 17 years or older; Method of use as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older; Method of use for treatment of partial-onset seizures in patients 4 years of age and older
Dosage: SOLUTION;INTRAVENOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic